Consensus Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Real-time Estimate Cboe BZX Other stock markets 10:19:15 2024-04-23 am EDT			5-day change	1st Jan Change
42.02 ^USD	-0.18%		+1.55%	-1.06%

Apr. 18	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
Apr. 18	Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	MT

Evolution of the average Target Price on Cerevel Therapeutics Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4f8855719c8e1654fe1f25d2.l_B_VfNkKGdaBTQK19I0qYiKw8ctZfZLL63guveTfgU.r7QQL6lReS4caHFSmYsC-tzlhYV6CKYmGuyz0pz7MDL9qBQ7iyceDzVqWw~5a92dbc5313a978d4afbf76fc4e80986

Analyst Recommendations on Cerevel Therapeutics Holdings, Inc.

Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	Dec. 28	MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	Dec. 22	MT
TD Cowen Downgrades Cerevel Therapeutics to Market Perform From Outperform, Price Target is $45	Dec. 08	MT
HC Wainwright Downgrades Cerevel Therapeutics to Neutral From Buy, Raises Price Target to $45 From $41	Dec. 07	MT
Are rate cuts are coming early next year?	Dec. 07
Cantor Fitzgerald Downgrades Cerevel Therapeutics to Neutral From Overweight, Raises Price Target to $45 From $38	Dec. 07	MT
Piper Sandler Downgrades Cerevel Therapeutics to Neutral From Overweight, Price Target is $45	Dec. 07	MT
Piper Sandler Starts Cerevel Therapeutics Holdings at Overweight, $33 Price Target	23-09-28	MT
Mizuho Cuts Price Target on Cerevel Therapeutics to $25 From $29, Keeps Neutral Rating	23-08-07	MT
Morgan Stanley Adjusts Price Target on Cerevel Therapeutics to $42 From $46, Maintains Overweight Rating	23-08-03	MT
HC Wainwright Adjusts Price Target on Cerevel Therapeutics to $41 From $45, Maintains Buy Rating	23-08-03	MT
BofA Securities Downgrades Cerevel Therapeutics Holdings to Neutral From Buy, Adjusts Price Target to $31 From $36	23-08-03	MT
Berenberg Bank Adjusts Cerevel Therapeutics Price Target to $24 From $22, Maintains Hold Rating	23-08-03	MT
Goldman Sachs Adjusts Price Target on Cerevel Therapeutics to $30 From $31, Keeps Neutral Rating	23-05-23	MT
Mizuho Securities Adjusts Cerevel Therapeutics Price Target to $29 From $26, Maintains Neutral Rating	23-05-08	MT
Wells Fargo Upgrades Cerevel Therapeutics Holdings to Overweight From Equalweight, Price Target is $30	23-05-04	MT
TD Cowen Initiates Cerevel Therapeutics Holdings at Outperform	23-04-10	MT
JPMorgan Downgrades Cerevel Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $29 From $40	23-03-17	MT
Berenberg Bank Resumes Coverage on Cerevel Therapeutics With Hold Rating, $22 Price Target	23-03-16	MT
Mizuho Cuts Price Target on Cerevel Therapeutics to $26 From $28, Keeps Neutral Rating	23-03-09	MT
Morgan Stanley Adjusts Price Target on Cerevel Therapeutics Holdings to $40 From $50, Maintains Overweight Rating	23-02-23	MT
Wells Fargo Downgrades Cerevel Therapeutics Holdings to Equalweight From Overweight, Adjusts Price Target to $30 From $38	23-02-23	MT
HC Wainwright Adjusts Price Target on Cerevel Therapeutics to $45 From $48, Maintains Buy Rating	23-02-23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

42.1 USD

Average target price

44.78 USD

Spread / Average Target

+6.36%

High Price Target

45 USD

Spread / Highest target

+6.89%

Low Price Target

43 USD

Spread / Lowest Target

+2.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cerevel Therapeutics Holdings, Inc.

Mizuho Securities
JPMorgan Chase
Jefferies & Co.
TD Cowen
HC Wainwright
Piper Sandler
Cantor Fitzgerald
Morgan Stanley
BofA Securities
Berenberg Bank
Goldman Sachs
Wells Fargo Securities
Loop Capital
Evercore ISI
Stifel Nicolaus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar